secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001628280-26-004738
Event type: debt
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year
---------------------------------------------------------------------

- Repricing amendment reduces interest rate margin by 50 bps to SOFR+3.00% or Base Rate+2.00%.
- Total Amendment No. 2 Term Loans of ~$2.095B, including ~$134.7M new term loan.
- Annualized cash interest savings estimated at ~$11 million.
- Maturity unchanged at August 1, 2032.
- Proceeds used to refinance existing Amendment No. 1 Term Loans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/amrx-20260202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-004738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer